T cell senescence is a key factor in immune dysfunction and is closely related to the development of malignant lung tumors. Senescent T cells have reduced ability to recognize and eliminate tumor cells, leading to the formation of a suppressive tumor microenvironment. This study discusses the characteristics, mechanisms, and expression of T cell senescence in malignant lung tumors and the treatment strategies. T cell senescence is associated with immune senescence, which is characterized by the progressive loss and dysfunction of the immune system. T cell senescence is marked by morphological changes, reduced telomere length, and increased expression of senescence-associated secretory phenotype (SASP) factors. These factors contribute to chronic inflammation and promote tumor progression. T cell senescence can also lead to immune evasion and reduced efficacy of immunotherapy. The mechanisms of T cell senescence include activation of age-related pathways, telomere shortening, mitochondrial dysfunction, and inflammatory stimulation. These mechanisms are closely related to the development of malignant tumors and the progression of cancer. Therapeutic strategies to reverse T cell senescence include blocking signaling pathways, enhancing mitochondrial function, maintaining telomere length, and anti-inflammatory therapy. These strategies aim to improve the effectiveness of immunotherapy and the prognosis of lung cancer. The study highlights the importance of understanding T cell senescence in the context of malignant lung tumors and the potential for developing new therapeutic approaches to combat cancer.T cell senescence is a key factor in immune dysfunction and is closely related to the development of malignant lung tumors. Senescent T cells have reduced ability to recognize and eliminate tumor cells, leading to the formation of a suppressive tumor microenvironment. This study discusses the characteristics, mechanisms, and expression of T cell senescence in malignant lung tumors and the treatment strategies. T cell senescence is associated with immune senescence, which is characterized by the progressive loss and dysfunction of the immune system. T cell senescence is marked by morphological changes, reduced telomere length, and increased expression of senescence-associated secretory phenotype (SASP) factors. These factors contribute to chronic inflammation and promote tumor progression. T cell senescence can also lead to immune evasion and reduced efficacy of immunotherapy. The mechanisms of T cell senescence include activation of age-related pathways, telomere shortening, mitochondrial dysfunction, and inflammatory stimulation. These mechanisms are closely related to the development of malignant tumors and the progression of cancer. Therapeutic strategies to reverse T cell senescence include blocking signaling pathways, enhancing mitochondrial function, maintaining telomere length, and anti-inflammatory therapy. These strategies aim to improve the effectiveness of immunotherapy and the prognosis of lung cancer. The study highlights the importance of understanding T cell senescence in the context of malignant lung tumors and the potential for developing new therapeutic approaches to combat cancer.